Previous 10 | Next 10 |
2023-06-29 13:27:29 ET Summary A major catalyst may arrive tomorrow for BioMarin as the FDA announces whether it will approve hemophilia gene therapy Roctavian. The drug is already approved in Europe, although pricing disputes are hindering sales. That ought not to be a problem in...
2023-06-23 15:00:37 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...
BioMarin to Present ROCTAVIAN™ (valoctocogene roxaparvovec) Data from Longest and Largest Hemophilia Gene Therapy Clinical Trial Program at the International Society on Thrombosis and Haemostasis (ISTH) 2023 Congress PR Newswire New Data to be Presented for ROCTAVIAN fr...
2023-06-19 05:16:46 ET Summary Pharma/biotechnology and healthcare providers are slightly undervalued relative to 11-year averages. Healthcare equipment is the most overvalued subsector. Fast facts on PBE, a genomics ETF. 10 healthcare stocks cheaper than their peers in Ju...
2023-06-07 08:55:15 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Navigating the turbulent waters in the biotech space is no mean feat. With the sector’s inherent volatility due to testing clinical trials and regulatory hurdles, the road toward market ...
2023-06-01 05:16:01 ET Summary Baker Brothers' 13F portfolio value increased from $16.65B to $18.38B, with the largest five stakes in Seagen, Incyte, BeiGene, ACADIA Pharma, and Madrigal Pharma. The firm disposed of its stakes in Ascendis Pharma A/S and Horizon Therapeutics, while...
2023-05-15 06:29:07 ET Summary We put BridgeBio Pharma, Inc. in the spotlight for the first time since last summer as the company continues to have buyout speculation around it. BridgeBio also has had some positive recent trial developments and executed a needed capital raise in M...
2023-05-06 16:00:00 ET "Health Care has generated the strongest earnings growth of sectors historically....," the health care team writes. "An aging population is also a secular tailwind for the sector." Regarding current valuations, they added, "pharma trades at a near-record d...
BioMarin to Participate in Bank of America 2023 Health Care Conference PR Newswire SAN RAFAEL, Calif. , May 4, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Brian Mueller , Executive Vice President, Chief Financial Offi...
2023-04-26 21:05:20 ET Biomarin Pharmaceutical, Inc. (BMRN) Q1 2023 Earnings Conference Call April 26, 2023, 16:30 ET Company Participants Traci McCarty - Group VP, IR Jean-Jacques Bienaime - Chairman & CEO Jeffrey Ajer - Chief Commercial Officer Henry Fu...
News, Short Squeeze, Breakout and More Instantly...
BioMarin Pharmaceutical Inc. Company Name:
BMRN Stock Symbol:
NASDAQ Market:
BioMarin Pharmaceutical Inc. Website:
2024-07-10 03:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-27 14:15:03 ET Scotiabank analyst issues UNDERPERFORM recommendation for BMRN on June 27, 2024 12:01PM ET. The previous analyst recommendation was Underperform. BMRN was trading at $82.885 at issue of the analyst recommendation. The overall analyst consensus : BU...
2024-06-27 14:15:02 ET Wells Fargo analyst issues SECTOR PERFORM recommendation for BMRN on June 27, 2024 12:01PM ET. The previous analyst recommendation was Sector Perform. BMRN was trading at $82.885 at issue of the analyst recommendation. The overall analyst consensus...